title: MPL mutations and palpable splenomegaly are independent risk factors for fibrotic progression in essential thrombocythemia.
authors: Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
authors: M
authors: M
authors: Haider
authors: Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
authors: Y C
authors: YC
authors: Elala
authors: Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
authors: N
authors: N
authors: Gangat
authors: Division of Hematopathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
authors: C A
authors: CA
authors: Hanson
authors: Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
authors: A
authors: A
authors: Tefferi
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D020022:Genetic Predisposition to Disease; D006801:Humans; D008297:Male; D008875:Middle Aged; D009154:Mutation; D010173:Palpation; D055728:Primary Myelofibrosis / Q000175:diagnosis* / Q000235:genetics* / Q000473:pathology; D011379:Prognosis; D053628:Receptors, Thrombopoietin / Q000235:genetics*; D012307:Risk Factors; D013163:Splenomegaly / Q000150:complications / Q000175:diagnosis* / Q000235:genetics; D013920:Thrombocythemia, Essential / Q000150:complications / Q000235:genetics* / Q000473:pathology*
chemical_list: D053628:Receptors, Thrombopoietin; C082218:MPL protein, human